Rapid communication Open Access
Like 0


We compared the risk of severe COVID-19 during two periods 2021 and 2022 when Delta and Omicron, respectively, were the dominating virus variants in Scania county, Sweden. We adjusted for differences in sex, age, comorbidities, prior infection and vaccination. Risk of severe disease from Omicron was markedly lower among vaccinated cases. It was also lower among the unvaccinated but remained high (> 5%) for older people and middle-aged men with two or more comorbidities. Efforts to increase vaccination uptake should continue.


Article metrics loading...

Loading full text...

Full text loading...



  1. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. SARS-CoV-2 Omicron VOC transmission in Danish households. medRxiv. 2021:2021.12.27.21268278. . https://doi.org/10.1101/2021.12.27.21268278 
  2. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv. 2022:2021.12.30.21268565. https://doi.org/10.1101/2021.12.30.21268565
  3. Ulloa AC, Buchan SA, Daneman N, Brown KA. Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv. 2021:2021.12.24.21268382. https://doi.org/10.1101/2021.12.24.21268382
  4. Bager P, Wohlfahrt J, Bhatt S, Edslev S, Sieber R, Ingham A, et al. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 Omicron relative to Delta: a Danish cohort study. SSRN. 2022. Preprint. .
  5. Ferguson N, Ghani A, Hinsley W, Volz E. Report 50 - Hospitalisation risk for Omicron cases in England. London: Imperial College; 2021. Available from: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-50-severity-omicron
  6. Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in southern Sweden. Infect Dis (Lond). 2022;54(2):128-33. PMID: 34586934 
  7. Björk J, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, et al. Surveillance of COVID-19 vaccine effectiveness – a real-time case-control study in southern Sweden. medRxiv. 2021: 2021.12.09.21267515. . https://doi.org/10.1101/2021.12.09.21267515 
  8. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-67.  https://doi.org/10.1007/s10654-009-9350-y  PMID: 19504049 
  9. Lägesbild COVID-19 i Skåne. Sekvensering av SARS-CoV-2. [COVID-19 situation in Scania. SARS-CoV-2 sequencing]. Kristianstad: Scania County Council; 2022. Swedish. Available from: https://www.skane.se/digitala-rapporter/lagesbild-covid-19-i-skane/sekvensering
  10. Dean NE. Re: "Measurement of vaccine direct effects under the test-negative design". Am J Epidemiol. 2019;188(4):806-10.  https://doi.org/10.1093/aje/kwz019  PMID: 30689690 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error